Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
18.14 USD | +0.17% | +3.49% | +65.36% |
May. 10 | Wedbush Raises Edgewise Therapeutics' PT to $31 From $26, Keeps Outperform Rating | MT |
May. 09 | Edgewise Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+65.36% | 1.69B | |
+39.06% | 50.93B | |
-0.21% | 42.12B | |
+49.62% | 42.05B | |
-7.20% | 29.18B | |
+12.98% | 26.02B | |
-22.44% | 18.9B | |
+8.26% | 13.21B | |
+24.54% | 12.17B | |
+29.91% | 12.16B |
- Stock Market
- Equities
- EWTX Stock
- News Edgewise Therapeutics, Inc.
- Goldman Sachs Adjusts Edgewise Therapeutics' Price Target to $5 from $8, Keeps Neutral Rating